Cure Parkinson’s International Linked Clinical Trials (iLCT) Pipeline Research Acceleration Programme is welcoming applications to investigate secukinumab in an alpha-synuclein model of Parkinson’s. Secukinumab has been evaluated twice by the iLCT committee, first in 2018 and again in 2025 due to new evidence being published. The committee have suggested that additional data is needed before secukinumab can progress into clinical trial for Parkinson’s, specifically how it performs in alpha-synuclein models of the condition. We encourage researchers with expertise in alpha synuclein models of Parkinson’s, across academia and industry, to consider applying to this funding call.
Applications are accepted until 11.59pm Tuesday, 7 April 2026.
Further InformationPosted on 12/02/2026
